Pactiv Evergreen Proves Adjusted EBITDA Guidance In The Range Of $755M-$780M For FY23 And ~$160M For Q1 Of 2023
Outlook
The Company is unable to provide a reconciliation of forward-looking Adjusted EBITDA without unreasonable effort because of the uncertainty and potential variability in amount and timing of our restructuring,